Combined tumour necrosis factor-α and tumour necrosis factor receptor genotypes could predict rheumatoid arthritis patients' response to anti-TNF-α therapy and explain controversies of studies based on a single polymorphism [1]

Rheumatology

Volumn 46, Issue 6, 2007, Pages 1034-1035

  Chatzikyriakidou, A ^a   Georgiou, I ^a   Voulgari, P V ^a   Venetsanopoulou, A I ^a   Drosos, A A ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

INFLIXIMAB; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; CORRELATION ANALYSIS; DRUG EFFICACY; DRUG RESPONSE; FEMALE; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETIC TRANSCRIPTION; GENETIC VARIABILITY; GENOTYPE; HOMOZYGOSITY; HUMAN; LETTER; MAJOR CLINICAL STUDY; MALE; PHARMACOGENETICS; PREDICTION; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SCORING SYSTEM; SINGLE NUCLEOTIDE POLYMORPHISM; WILD TYPE;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; RECEPTORS, TUMOR NECROSIS FACTOR; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 34447296681     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kem041     Document Type: Letter

References (10)

1. Morita C, Horiuchi T, Tsukamoto H et al. Association of tumor necrosis factor receptor type II polymorphism 196R with Systemic lupus erythematosus in the Japanese: Molecular and functional analysis. Arthritis Rheum 2001;44:2819-27.
2. Mugnier B, Balandraud N, Darque A, Roudier C, Roudier J, Reviron D. Polymorphism at position -308 of the tumor necrosis factor alpha gone influences outcome of infliximab therapy in rheumatoid arthritis. Arthritis Rheum 2003;48:1849-52.
3. Criswell LA, Lum RF, Turner KN et al. The influence of genetic variation in the HLA-DRB1 and LTA-TNF regions on the response to treatment of eady rheumatoid arthritis with mathotrexate or etanarcept. Arthritis Rheum 2004;50:2750-6.
4. Kang CP, Lee KW, Yoo DH, Kong C. Bae SC. The influence of a polymorphism at position -857 of the tumour necrosis factor alpha gone on clinical response to etanercept therapy in rheumatoid arthritis. Rheumatology 2005;44:547-52.
5. Padyukov L, Lamps J, Heimburg M et al. Genetic markers for the efficacy of tumour necrosis factor blocking therapy in rheumatoid arthritis. Ann Rheum Dis 2003;62:526-9.
6. Voulgari PV, Alamanos Y, Nikas SN, Bougias DV, Temekonidis TI, Drosos AA. lnfliximab therapy in established rheumatoid arthritis: An observational study. Am J Med 2005;118:515-20.
7. Raymond M, Rousset F. An exact test for population differentiation. Evolution 1995;49:1280-3.
8. Fabris M, Tolusso B, di Poi E, Assaloni R, Sinigaglia L, Ferraccioli G. Tumor necrosis factor-alpha receptor II polymorphism in patients from southern Europe with mild-moderate and severe rheumatoid arthritis. J Rheumatol 2002;29:1847-50.
9. Soga Y, Nishimura F, Ohyama H, Maeda H, Takashiba S, Murayama Y. Tumor necrosis factor-alpha gene (TNF-alpha) -1031/-863, -857 single-nucleotide polymorphisms, (SNPs) are associated with severe adult periodontitis in Japanese. J Clin Periodontol 2003;30:524-31.
10. Kaijzel EL, Bayley JP, van Krugtan MV et al. Allele-specific quantification of tumor necrosis factor alpha (TNF) transcription and the role of promoter polymorphisms in rheumatoid arthritis patients and healthy individuals. Genes Immun 2001;2:135-44.